|
Summary
May 2007, Vol. 8, No. 7, Pages 975-988
, DOI 10.1517/14656566.8.7.975
Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcersAndrea Morgner1Consultant, Medical Department I, University Hospital, Fetscherstrasse 74; D-01307 Dresden, Germany 2Area Director Gastroenterology, Medical Department I, University Hospital, Fetscherstrasse 74; D-01307 Dresden, Germany 3Head of the Department of Internal Medicine and Gastroenterology, Faculty of Medicine, University of Essen, Germany 4Department of Medicine, Jung-Stilling Hospital Siegen, Academic Teaching Hospital University of Bonn, Wichernstrasse 40, D-57074 Siegen, Germany. J.Labenz@t-online.de Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used drug classes. However, many patients complain of dyspeptic symptoms impairing their quality of life: ~ 20% of patients taking NSAIDs show endoscopic ulcers with or without symptoms, and up to 2% of chronic NSAID users will develop serious complications each year, such as bleeding or perforation, which are the cause of death in many patients. Coprescription of a proton pump inhibitor is one established option for the healing and prevention of NSAID-associated lesions of the upper gastrointestinal tract in patients at risk. Recent studies evaluated the clinical efficacy of esomeprazole in the management of gastrointestinal problems associated with the intake of selective and non-selective NSAIDs and aspirin. Forward Links to Citing ArticlesShaojun Shi, Ulrich Klotz. (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. European Journal of Clinical Pharmacology 64:10, 935-951 Online publication date: 1-Nov-2008. CrossRef Kate McKeage, Stephanie K A Blick, Jamie D Croxtall, Katherine A Lyseng-Williamson, Gillian M Keating. (2008) Esomeprazole. Drugs 68:11, 1571-1607 Online publication date: 1-Feb-2008. CrossRef |
|





Author for correspondence
TOC Alert